Intrexon to Announce Fourth Quarter and Full Year 2014 Financial Results on Monday, March 2, 2015
GERMANTOWN, Md., Feb. 23, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) today announced it will release fourth quarter and full year 2014 financial results after the market closes on March 2, 2015.  The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update. The conference call may be accessed by dialing 1-888-346-3959 (Domestic US) and 1-412-902-4262 (International) and asking to join the "Intrexon Conference Call."  Participants may also access the live webcast through Intrexon's website in the Investors section under Calendar of Events. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in...
Living Biofactories in Your Prescription Bottle?
Belgium's ActoGeniX to Join Intrexon Bringing New Generation of Orally Delivered Biotherapeutics GERMANTOWN, Md. and GHENT, Belgium, Feb. 13, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has entered into a definitive agreement to acquire ActoGeniX, a European clinical stage biopharmaceutical company forging a new frontier in cellular therapeutics.  The proprietary TopAct™ platform developed by ActoGeniX enables the molecular engineering of food-grade microbes (Lactococcus lactis) to generate biologically-contained ActoBiotics™ for in situ expression and secretion of novel biotherapeutic proteins and peptides including cytokin...
Intrexon Announces Closing of $116 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
GERMANTOWN, Md., Jan. 27, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today the closing of its previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 562,500 shares of common stock at the public offering price of $27.00 per share. The exercise of the underwriters' option brought the total number of shares of common stock sold by Intrexon to 4,312,500 shares and increased the total gross proceeds raised in the offering to approximately $116.4 million, before deducting the underwriting discounts, commissions and estimated expenses. J.P. Morgan and B...
Intrexon to Acquire Remaining Stake in Exemplar Genetics
Intrexon Collaborators Obtain Access to Premier Pipeline of Large Animal Research Models and Custom Animal Development GERMANTOWN, Md. and SIOUX CENTER, Iowa, Jan. 26, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has launched a tender offer to acquire the remaining stake in Exemplar Genetics, a company committed to enabling the study of life-threatening human diseases.  Utilizing its proprietary technologies in animal genetics, Exemplar has developed a broad pipeline of transgenic swine models for research and development of heart disease, cancer, cystic fibrosis, cardiac arrhythmia, neuromuscular and neurodegenerative disorder...
1